Optimizing Care of the Patient with Cirrhosis to Prevent Decompensation

Overview

This lecture by Prof. Simone Strasser addresses the prevention of decompensation in patients with cirrhosis, with a focus on identifying at-risk patients, managing portal hypertension, and optimising clinical care strategies including alcohol assessment and metabolic risk factor management.

Key Clinical Topics

• Identifying patients at risk for first and further decompensation
• Managing clinically significant portal hypertension
• Preventing decompensation events: ascites, variceal bleeding, and hepatic encephalopathy (HE)
• Optimising surveillance and supportive care
• Timing of liver transplant referral
• Role of alcohol assessment in fatty liver disease
• Etiology-specific treatment strategies in cirrhosis

Key Learning Points

• Compensated to decompensated cirrhosis (CACld) transition: A pivotal pathophysiological and prognostic milestone; preventing the first decompensating event is a primary clinical goal
• Treatable etiologies: Hepatitis B and C have effective antiviral therapies; MASLD requires weight loss, exercise, and cardiometabolic risk factor control; PBC treated with UDCA, elafibranor, or obeticholic acid; haemochromatosis with phlebotomy; autoimmune hepatitis and Wilson's disease have targeted therapies
• Etiologic cure is insufficient alone: Patients with resolved liver disease etiology but ongoing obesity, type 2 diabetes, or other metabolic comorbidities remain at elevated risk of progression and decompensation
• Metabolic risk factors as decompensation drivers: Diabetes and obesity are independent and significant drivers of decompensation in cirrhotic patients
• Alcohol underreporting: A substantial proportion of patients self-reporting no alcohol consumption have significant alcohol use when objectively tested; PEth testing is recommended to accurately identify alcohol consumption
• Dynamic nature of alcohol consumption: Alcohol intake changes over time; reassessment must be ongoing rather than once-off
• Screening tools: A single-question tool or full AUDIT-C questionnaire should supplement or replace simple verbal inquiry; PEth testing is increasingly available and recommended for clinical use
• Key consensus references: Australian Gastroenterological Society consensus statement on portal hypertension and cirrhosis (published in *Hepatology Communications*); Baveno 8 consensus workshop (journal pre-proof available in *Journal of Hepatology*)

Clinical Data & Study Results

• Case patient (Mary): 60-year-old woman with BMI 35, type 2 diabetes, hypertension, hyperlipidemia; labs include albumin 3.2 g/dL, platelets 101 × 10⁹/L, HbA1c 8.2%, FIB-4 of 4.57, and liver stiffness measurement of 29 kPa on transient elastography; Child's A6, MELD 10 — consistent with compensated MASLD-related cirrhosis
• Queensland hospital cohort: In patients with compensated cirrhosis, a concurrent diagnosis of type 2 diabetes was associated with a 14.5-fold increased risk of progression to decompensated cirrhosis
• PEth study (>6,000 MASLD patients): Despite self-reported abstinence or minimal intake, 14% were reclassified into the ALD range and 20% into the MetALD range — totalling >34% with significant occult alcohol consumption; alcohol co-exposure worsened major adverse liver outcomes
• Korean nationwide cohort (~3 million individuals): Dynamic changes in alcohol consumption correlated with dynamic changes in liver-related event risk; patients who reduced alcohol intake from ALD levels showed improved prognosis, while continued high consumption worsened outcomes

Practical Takeaways

• Screen all patients with fatty liver disease for alcohol using PEth testing, not self-report alone
• Reassess alcohol consumption longitudinally at every clinic visit, as intake patterns change over time
• Use structured tools such as the AUDIT-C rather than informal verbal inquiry
• Actively manage metabolic comorbidities — particularly type 2 diabetes and obesity — even